Rasburicase Injection

Price 10 USD ($)/ Box

Get a Price/Quote

MOQ : 100 Boxes

Rasburicase Injection Specification

Dosage Form
Injection

Indication
Tumor Lysis Syndrome, Hyperuricemia associated with chemotherapy

Salt Composition
Rasburicase

Enzyme Types
Oxidoreductase (Urate Oxidase)

Feature
Fast-acting uricolytic enzyme; recombinant technology

Ingredients
Rasburicase (Recombinant Urate Oxidase), Excipients

Application
Medical/Pharmaceutical use for rapid reduction of plasma uric acid

Ph Level
7.0 - 8.0

Temperature Needed For Fermentation
25C - 30C

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Enzymatic Activity
Recombinant urate oxidase enzymatic conversion activity

Storage Instructions
Cool & Dry Place

Shelf Life
24 months

Rasburicase Injection Trade Information

Minimum Order Quantity
100 Boxes

FOB Port
Mundra Port, Nhava Sheva

Supply Ability
100000 Boxes Per Month

Delivery Time
7-10 Days

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Main Domestic Market
All India

About Rasburicase Injection

We are leading exporter and manufacturer of Rasburicase Injection.

Uses

Rasburicase is used in the treatment of ovarian cancer, blood cancer, hemorrhagic cystitis and methotrexate toxicity.
How it works

Rasburicase, a urate-oxidase enzyme, works by eliminating the excess uric acid that is produced when cancer cells are destroyed.
Common side effects
Nausea, Headache, Vomiting, Rash, Urticaria, Fever, Diarrhoea

TAG

Rasburicase Injection exporter, Rasburicase Injection manufacturer

Rasburicase Injection supplier, Rasburicase Injection manufacturer in India,

Rasburicase Injection exporter in India.

How Rasburicase Injection Works

Rasburicase is a recombinant urate oxidase enzyme that converts uric acid into allantoin, a more water-soluble compound easily eliminated by the kidneys. This process is particularly beneficial in managing rapid increases in uric acid levels related to chemotherapy-induced tumor lysis, offering swift uric acid reduction.

When and Where to Use Rasburicase

Rasburicase Injection is administered in healthcare settings, typically in hospitals, before or during chemotherapy in patients at risk for Tumor Lysis Syndrome or elevated uric acid. The medication is given by intravenous infusion only after reconstitution with the supplied sterile diluent by qualified professionals.

Key Benefits and Special Features

This injection begins acting quickly to manage hyperuricemia, significantly lowering the risk of kidney complications during cancer treatment. The recombinant manufacturing process ensures purity and safety. It is indicated for medical and pharmaceutical use and features a 24-month shelf life, making it suitable for storage and timely use by institutions.

FAQs of Rasburicase Injection:

Q: How is Rasburicase Injection prepared and administered?

A: Rasburicase is supplied as a lyophilized powder in 1.5 mg vials and should be reconstituted with the provided sterile diluent just before intravenous infusion. The solution is administered intravenously by a healthcare professional in a medical setting.

Q: What is the primary benefit of using Rasburicase Injection in patients?

A: The main benefit is rapid reduction of plasma uric acid levels, which helps prevent kidney damage and manage Tumor Lysis Syndrome during chemotherapy by metabolizing uric acid into a more soluble and easily excreted form.

Q: When should Rasburicase Injection be used?

A: Rasburicase is typically used before or during chemotherapy in patients at risk for or experiencing Tumor Lysis Syndrome or significant hyperuricemia, under the supervision of healthcare providers.

Q: Where should Rasburicase Injection be stored?

A: Rasburicase vials should be kept in a cool, dry place as per the storage instructions to maintain product efficacy throughout its 24-month shelf life.

Q: What precautions should be taken before administering Rasburicase?

A: Patients should be screened for G6PD deficiency and hypersensitivity to rasburicase. It is crucial to monitor for any allergic reactions or hemolysis during and after administration.

Q: How does the recombinant manufacturing process benefit the safety of Rasburicase?

A: Rasburicase is produced using recombinant DNA technology in Aspergillus flavus, ensuring consistency, purity, and minimized risk of contaminants, resulting in a high-quality pharmaceutical enzyme preparation.

Q: What kind of patients should avoid Rasburicase Injection?

A: Individuals with known G6PD deficiency or hypersensitivity to rasburicase should not receive this medication, as it may cause severe hemolysis or allergic reactions.

Tell us about your requirement